ASND vs BBIO
Ascendis Pharma A/S and BridgeBio Pharma, Inc., both Healthcare
Ascendis Pharma A/S is the larger company at $17B against $14B. Over the past year BBIO returned +25% against +16% for ASND. The RyuScore puts ASND ahead, 9 against 7 out of 100.
| Figure | ASND | BBIO |
|---|---|---|
| Last close | $229 | $65.35 |
| Market cap | $17B | $14B |
| 1-year return | +16% | +25% |
| 5-year return | +49% | +34% |
| RyuScoresector-relative, 1–10 | 9/100 | 7/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Ascendis Pharma A/S
Revenue of $248M in Q4 2025, net income null.
BridgeBio Pharma, Inc.
Revenue of $244M in Q2 2026, net income null. Its largest reported line is License Services And Royalty, 45% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.